Chong He

TL;DR: This review discusses the recent progress reported in studies of distinct types of regulatory immune cells in the gut, including intestinal intraepithelial lymphocytes, Foxp3+ regulatory T cells, regulatory B cells, alternatively activated macrophages, dendritic cells, and innate lymphoid cells and how dysfunction of this immune regulatory system contributes to intestinal diseases such as IBD.

TL;DR: The data indicate that miR-10a is decreased in the inflamed mucosa of IBD and downregulates mucosal inflammatory response through inhibition of IL-12/IL-23p40 and NOD2 expression, and blockade of Th1/Th17 cell immune responses.

TL;DR: A novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of patients with IBD promotes Th17 cell differentiation through downregulation of SNIP1 is revealed and may serve as a novel therapeutic approach in the treatment of IBD.

TL;DR: There was an inverse correlation between levels of BTG1 mRNA and levels of MIR301A in inflamed mucosal tissues from patients with active IBD and CAC compared with controls.

TL;DR: The concentrations of LPS and BG were demonstrated to be significantly downregulated in the sera of A-CD patients 12 weeks after IFX treatment, suggesting that blockade of TNF could inhibit bacterial endotoxin absorption, partially through improving intestinal mucosal barrier.